Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular insights into regulation of JAK2 in myeloproliferative neoplasms.

Blood - 28 May 2015

Silvennoinen Olli, Hubbard Stevan R

Abstract excerpt

The critical role of Janus kinase-2 (JAK2) in regulation of myelopoiesis was established 2 decades ago, but identification of mutations in the pseudokinase domain of JAK2 in myeloproliferative neoplasms (MPNs) and in other hematologic malignancies highlighted the role of JAK2 in human disease. These findings have revolutionized the diagnostics of MPNs and led to development of novel JAK2 therapeutics. However,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Gene Expression Regulation, Enzymologic
Share to Gene Expression Regulation, Neoplastic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hematologic Neoplasms

Share to Homeostasis

Share to Janus Kinase 2

Share to Models, Molecular

Share to Myeloproliferative Disorders

Share to Protein Structure, Tertiary

Source

Open in PubMed Open full text

Identifiers

PMID: 25824690
DOI: 10.1182/blood-2015-01-621110
PMCID: PMC4447858

Genes

JAK2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular insights into regulation of JAK2 in myeloproliferative neoplasms.PMID 25824690Read ↗

Jak2: normal function and role in hematopoietic disorders.Semantic proximity Read ↗

Activating Janus kinase pseudokinase domain mutations in myeloproliferative and other blood cancers.Semantic proximity Read ↗

JAK-mutant myeloproliferative neoplasms.Semantic proximity Read ↗

JAK2 inhibition for the treatment of hematologic and solid malignanciesSemantic proximity Read ↗

The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling.Semantic proximity Read ↗

Next-generation JAK inhibitors in the treatment of myeloproliferative neoplasms.Semantic proximity Read ↗

JAK2 in Myeloproliferative Neoplasms: Still a ProtagonistSemantic proximity Read ↗

The JAK2(V617F) tyrosine kinase mutation in myeloproliferative disorders: Summary of published literature and a perspective.Semantic proximity Read ↗

The JAK2 mutation.Semantic proximity Read ↗

The JAK2V617F tyrosine kinase mutation in myeloproliferative disorders: status report and immediate implications for disease classification and diagnosis.Semantic proximity Read ↗

New insights into the structure and function of the pseudokinase domain in JAK2.Semantic proximity Read ↗

JAK2 inhibitors in the treatment of myeloproliferative neoplasms.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.